Abstract:Metformin inhibits non‐diabetic HCC induced by chronic liver injury. Metformin decreases Cyp26a1 and thereafter increases the level of atRA. Pro‐tumour CD8+ T cells are increased significantly during hepatocarcinogenesis, and both metformin and atRA reverse this effect. AMPK pathway is suppressed during tumour formation and metformin decreases Cyp26a1 expression through modulating AMPK/STAT3/Gadd45β/JNK/c‐Jun pathway. Background Hepatocellular carcinoma (HCC) is a highly heterogeneous cancer with major challenges in both prevention and therapy. Metformin, adenosine monophosphate‐activated protein kinase (AMPK) activator, has been suggested to reduce the incidence of HCC when used for patients with diabetes in preclinical and clinical studies. However, the possible effects of metformin and their mechanisms of action in non‐diabetic HCC have not been adequately investigated. Methods Fah−/− mice were used to construct a liver‐injury‐induced non‐diabetic HCC model for exploring hepatocarcinogenesis and therapeutic potential of metformin. Changes in relevant tumour and biochemical indicators were measured. Bulk and single‐cell RNA‐sequencing analyses were performed to validate the crucial role of proinflammatory/pro‐tumour CD8+ T cells. In vitro and in vivo experiments were performed to confirm Cyp26a1‐related antitumour mechanisms of metformin. Results RNA‐sequencing analysis showed that chronic liver injury led to significant changes in AMPK‐, glucose‐ and retinol metabolism‐related pathways in Fah−/− mice. Metformin prevented the formation of non‐diabetic HCC in Fah−/− mice with chronic liver injury. Cyp26a1 ddexpression in hepatocytes was significantly suppressed after metformin treatment. Moreover, downregulation of Cyp26a1 occurred in conjunction with increased levels of all‐trans‐retinoic acid (atRA), which is involved in the activation of metformin‐suppressed hepatocarcinogenesis in Fah−/− mice. In contrast, both CD8+ T‐cell infiltration and proinflammatory/pro‐tumour cytokines in the liver were significantly upregulated in Fah−/− mice during chronic liver injury, which was notably reversed by either metformin or atRA treatment. Regarding mechanisms, metformin regulated the decrease in Cyp26a1 enzyme expression and increased atRA expression via the AMPK/STAT3/Gadd45β/JNK/c‐Jun pathway. Conclusions Metformin inhibits non‐diabetic HCC by upregulating atRA levels and downregulating CD8+ T cells. This is the first reporting that the traditional drug metformin regulates the metabolite atRA via the Cyp26a1‐involved pathway. The present study provides a potential application of metformin and atRA in non‐diabetic HCC.

Metformin Inhibits the Prometastatic Effect of Sorafenib in Hepatocellular Carcinoma by Upregulating the Expression of TIP30.

Metformin Sensitizes Sorafenib to Inhibit Postoperative Recurrence and Metastasis of Hepatocellular Carcinoma in Orthotopic Mouse Models

Metformin promotes ferroptosis and sensitivity to sorafenib in hepatocellular carcinoma cells via ATF4/STAT3

Combination of Metformin and Sorafenib Suppresses Proliferation and Induces Autophagy of Hepatocellular Carcinoma Via Targeting the Mtor Pathway.

Metformin synergistically enhances the antitumour activity of Lenvatinib in hepatocellular carcinoma by altering AKT-FOXO3 signalling pathway

Metformin Attenuates Hepatoma Cell Proliferation by Decreasing Glycolytic Flux Through the HIF-1α/PFKFB3/PFK1 Pathway.

Metformin incombination with curcumin inhibits the growth, metastasis, and angiogenesis of hepatocellular carcinoma in vitro and in vivo.

The Mir-367-3p Increases Sorafenib Chemotherapy Efficacy to Suppress Hepatocellular Carcinoma Metastasis Through Altering the Androgen Receptor Signals

Metformin Resensitizes Sorafenib-Resistant HCC Cells Through AMPK-Dependent Autophagy Activation

Metformin Inhibits Hepatocellular Carcinoma Development by Inducing Apoptosis and Pyroptosis Through Regulating FOXO3

Genome-wide CRISPR screen identifies synthetic lethality between DOCK1 inhibition and metformin in liver cancer

Metformin Potentiates the Effects of Anlotinib in NSCLC via AMPK/mTOR and ROS-Mediated Signaling Pathways

Metformin synergistically sensitizes FLT3-ITD-positive acute myeloid leukemia to sorafenib by promoting mTOR-mediated apoptosis and autophagy

Metformin Decreases Il-22 Secretion To Suppress Tumor Growth In An Orthotopic Mouse Model Of Hepatocellular Carcinoma

Disrupting metformin adaptation of liver cancer cells by targeting the TOMM34/ATP5B axis

Low-dose metformin suppresses hepatocellular carcinoma metastasis via the AMPK/JNK/IL-8 pathway

Metformin Inhibits Human Non-Small Cell Lung Cancer by Regulating AMPK–CEBPB–PDL1 Signaling Pathway

Metformin sensitises hepatocarcinoma cells to methotrexate by targeting dihydrofolate reductase

Suppression of Natural Killer Cells by Sorafenib Contributes to Prometastatic Effects in Hepatocellular Carcinoma

Metformin reduces hepatocarcinogenesis by inducing downregulation of Cyp26a1 and CD8+ T cells

Metformin Sensitizes Hypoxia-Induced Gefitinib Treatment Resistance of HNSCC Via Cell Cycle Regulation and EMT Reversal